The WTA announces it will conduct a one-time SRY gene test on female players, a move that triggers debate within the tennis community. The test is intended to verify biological sex using the presence of the SRY gene.
Multiple outlets describe the announcement as contentious, with reactions split across players, advocates, and officials. Supporters argue it aims to create clarity and consistency in eligibility decisions, while critics say it could be discriminatory and harmful, and they question whether a single genetic test can reliably reflect sex and gender complexity. Some commentary focuses on the impact on affected athletes, including privacy and stigma, while others focus on what the WTA is trying to achieve in terms of policy and fairness.
The dispute highlights broader differences in how organizations and stakeholders view sex verification in sport. Outlets frame the controversy around concerns about scientific validity, ethical treatment of athletes, and the process used to introduce the testing policy, including how it is communicated and implemented.
